Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Overview
Atossa Therapeutics Inc (ATOS) is a clinical stage biopharmaceutical company that develops and markets innovative medicines, laboratory tests, and therapeutic delivery platforms focused on addressing unmet medical needs in oncology. With a primary emphasis on women’s breast health and breast cancer, the company is dedicated to advancing novel drug candidates and precision-targeted delivery systems, employing cutting-edge approaches such as selective estrogen receptor modulation and intraductal microcatheter technology.
Core Therapeutic Focus
The company’s flagship asset, (Z)-endoxifen, exemplifies its commitment to tackling critical challenges in breast cancer treatment. (Z)-endoxifen is a potent selective estrogen receptor modulator (SERM) that not only inhibits estrogen receptor activity but also facilitates its degradation. This dual action is strategically designed to address cases where resistance to traditional hormonal therapies exists, thus filling a significant therapeutic gap in oncology. Additionally, the formulation of (Z)-endoxifen is developed as an oral medication that bypasses the liver metabolism and gastric degradation issues, ensuring optimal bioavailability at therapeutic concentrations.
Innovative Drug Delivery Platforms
Beyond its core drug candidates, Atossa Therapeutics is also pioneering advanced delivery mechanisms to enhance therapeutic efficacy. The development of intraductal microcatheter technology represents a novel approach to deliver therapies directly to the site of breast cancer, thereby improving the targeting of treatments such as hormonal therapies, immunotherapies, and chimeric antigen receptor T-cell therapies. This targeted delivery strategy not only heightens the precision of treatment but also has the potential to reduce systemic side effects, contributing to an overall improved patient experience.
Clinical Development and Research Programs
Atossa’s development pipeline is robust, with multiple Phase 2 trials designed to evaluate the effectiveness of (Z)-endoxifen in diverse patient populations, including women with measurable breast density and those diagnosed with ductal carcinoma in situ. The company’s research initiatives extend to combination therapies, where (Z)-endoxifen is studied alongside other agents such as cyclin-dependent kinase (CDK) inhibitors, further broadening the therapeutic paradigm in breast cancer treatment. These programs underscore the company’s strategic emphasis on targeted oncology, employing rigorous clinical methods to substantiate the efficacy and safety of its novel therapies.
Intellectual Property and Market Position
Central to Atossa’s strategy is its strong intellectual property portfolio, which includes multiple issued U.S. patents and numerous pending applications. These patents cover both the composition of matter for (Z)-endoxifen and innovative formulation approaches, ensuring a competitive edge in the market. By protecting its technology and research investments, the company lays a solid foundation for long-term value creation, even as it navigates the challenges inherent to clinical stage development.
Competitive Landscape and Industry Expertise
Operating within the highly competitive biopharmaceutical industry, Atossa Therapeutics distinguishes itself through its integrated approach to drug development and delivery innovation. Its expertise in designing treatments that address both the efficacy and tolerability aspects of cancer care positions it uniquely among its peers. The company’s focus on precise molecular targeting and the development of therapeutics that are supported by robust scientific data bolsters its role as a knowledgeable and expertly positioned player in the oncology landscape.
Business Model and Operational Strategy
- Clinical Innovation: Concentrates on advancing clinical programs with a focus on unmet needs in breast cancer and breast health conditions.
- Targeted Delivery: Emphasizes pioneering approaches in delivering therapies directly to disease sites, using technologies like intraductal microcatheter systems.
- Intellectual Property: Leverages a strong portfolio of patents to secure its technological advancements and maintain market differentiation.
- Collaborative Research: Engages in strategic partnerships and clinical collaborations to enhance its research capabilities and validate its clinical hypotheses.
Conclusion
Atossa Therapeutics Inc exemplifies a focused, research-driven approach to addressing significant challenges in oncology. By combining novel therapeutic agents with innovative delivery systems, the company provides a comprehensive model for advancing personalized breast cancer treatment. Its commitment to enhancing patient outcomes through scientific rigor and technological innovation underscores its importance in the dynamic field of biopharmaceutical research. The detailed clinical programs, strategic intellectual property protections, and collaborative research efforts are all testaments to its expertise and nuanced understanding of complex oncology treatment paradigms.
Dr. Steven Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), shares effective tips for enhancing cloth Covid-19 masks, featured in FOX 26 Houston and his new book, "Stay Safe: A Physician's Guide to Survive Coronavirus." This guide compiles science-backed insights to alleviate pandemic-related concerns, offering practical solutions for better protection. Quay's innovative "salt spray" method, made from salt, water, and dish soap, enhances mask effectiveness. His book is available on Amazon, providing dozens of lifesaving recommendations for Covid-19 safety.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported a positive interim safety assessment from the first cohort of its Phase 1 clinical study for AT-301, a nasal spray drug candidate aimed at treating COVID-19. The study involved 8 healthy participants who received either a placebo or an active dose, leading to a favorable safety review. This milestone allows the company to proceed with patient enrollment for higher doses and repeated dose cohorts. The Phase 1 study, taking place in Australia, focuses on the safety and tolerability of AT-301, thus paving the way for further efficacy investigations.
Atossa Therapeutics (Nasdaq: ATOS) announced that CEO Dr. Steven Quay will present at the LD Micro 500 virtual conference on September 4, 2020, at 9:00 AM ET. This presentation will be followed by a live Q&A session for registered investors and attendees. Additionally, Dr. Quay is available for one-on-one virtual meetings from September 1-4, 2020. Atossa focuses on developing innovative medicines for unmet medical needs, particularly in breast cancer and COVID-19. For further details, visit www.atossatherapeutics.com.
Atossa Therapeutics (Nasdaq: ATOS) has announced the enrollment of the first cohort in a Phase 1 clinical study for its nasal spray drug candidate, AT-301, aimed at treating COVID-19. The initial cohort includes 8 healthy participants who received either a placebo or the active drug. The study, conducted in Australia, is designed to evaluate the safety and tolerability of AT-301. The company aims to complete enrollment quickly, emphasizing the potential of AT-301 to act as a protective barrier against COVID-19, which could significantly impact public health if successful.
Atossa Therapeutics (NASDAQ: ATOS) announced its Q2 2020 financial results, reporting no sustainable revenue during the quarter. Operating expenses decreased by 46% to approximately $3.94 million, primarily due to reduced research and administrative costs. Atossa received approval for a Phase 1 clinical study of its COVID-19 nasal spray, AT-301, in Australia, and reported promising in vitro results for its therapies. The company has approximately $7.5 million in cash, bolstered by an additional $4.3 million raised in July.
Atossa Therapeutics (NASDAQ: ATOS) has received ethics committee approval to initiate a Phase 1 clinical study in Australia for AT-301, a nasal spray drug aimed at treating COVID-19. Enrollment is expected to start within 30 days. The drug's unique mechanism targets the nasal cavity to enhance protection and potentially lower symptoms of COVID-19. The study will assess safety and tolerability in 32 participants and could influence future FDA applications. With rising COVID-19 cases in Australia, the trial is timely and significant for public health.
Atossa Therapeutics (Nasdaq: ATOS) has announced positive interim findings from an Expanded Access study of its oral Endoxifen for breast cancer treatment, which shows no recurrence of cancer in a patient after 18 months. The treatment did not cause common side effects associated with tamoxifen, and significant reductions in tumor markers Ki-67 (50%) and ER+ cells (22%) were observed. A Phase 2 study is ongoing, focusing on newly diagnosed patients, with all interim patients showing considerable Ki-67 reduction.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announces a webinar on July 30, 2020, hosted by CEO Dr. Steven Quay. The 30-minute event will discuss the company's breast cancer programs and advancements in two COVID-19 treatments. Registration is free via Tribe Public's website. Dr. Quay, a prominent figure in medical research, holds multiple patents and has contributed significantly to COVID-19 and breast cancer solutions. The event aims to provide insights into Atossa's progress and engage with investors.
Atossa Therapeutics (NASDAQ: ATOS) has contracted with Avance Clinical to conduct a clinical study of its nasal spray drug candidate, AT-301, aimed at treating COVID-19 in non-hospitalized patients. The double-blinded, randomized, placebo-controlled study will evaluate the safety of AT-301 in 32 healthy adults. The primary goal is to assess tolerability and local irritation, while secondary objectives include bronchospasm evaluations. Atossa plans to file for further regulatory approvals and aims to begin the study soon. The company has also filed provisional patents for AT-301.
Atossa Therapeutics (Nasdaq: ATOS) has announced positive in vitro results for its COVID-19 nasal spray, AT-301. The drug candidate demonstrated the ability to inhibit SARS-CoV-2 infectivity in VERO cells, suggesting potential efficacy in blocking virus entry into nasal cells. AT-301 aims to create a protective mucosal barrier in the nasal cavity, which could lower COVID-19 symptoms and infectivity. A Phase 1 clinical study is expected to commence soon. Atossa has filed provisional patents related to AT-301's formulation and methods of use.
FAQ
What is the current stock price of Atossa Therapeutics (ATOS)?
What is the market cap of Atossa Therapeutics (ATOS)?
What is the primary focus of Atossa Therapeutics Inc?
What is (Z)-endoxifen and why is it significant?
How does Atossa differentiate its drug delivery approach?
What stage is Atossa Therapeutics currently in?
How does the company strengthen its market position?
What are the core components of Atossa’s business model?
Who are the primary beneficiaries of Atossa’s therapies?
How does Atossa’s approach contribute to the field of oncology?
